skip to content »

Pathology & Immunology

Houston, Texas

Pathology and Immunology
Pathology & Immunology
not shown on screen

Faculty

Michael Ittmann M.D., Ph.D.William D. Tigertt Professor

Education

  • M.D., Case Western Reserve University, 1983
  • Ph.D., Biochemistry, Case Western Reserve University, 1982
  • Bachelor of Science, Biochemistry, Michigan State University, 1976

Internship

  • New York University School of Med., Anatomic Pathology, 1983-84

Residency

  • New York University School of Med., Anatomic Pathology, 1984-87

Post-doctoral Training

  • New York University School of Med., 1985-87

Specialty

  • Anatomic Pathology

Board Certification

  • Anatomic Pathology, 1987

Area of Interest

  • Prostate cancer
  • Genitourinary pathology

Current Position

  • Professor of Pathology, Baylor College of Medicine
  • Chief, Pathology and Laboratory Medicine, Michael E. DeBakey VAMC

Professional Positions Held

  • William D. Tigertt Professor, Department of Pathology, Baylor College of Medicine, Houston, TX, 07/2002-present
  • Associate Professor, Department of Pathology, Baylor College of Medicine, Houston, TX, 1997-2002
  • Assistant Professor, Department of Pathology, New York University School of Medicine, New York, NY, 1987-1997

Other Positions

  • Chief, Pathology and Laboratory Medicine, Michael E. DeBakey Dept of Veterans Affairs Med. Center, Houston, TX,
  • Staff Pathologist, Michael E. DeBakey Dept of Veterans Affairs Med. Center, Houston, TX
  • Staff Pathologist, New York Dept of Veterans Affairs Med. Center, New York, NY

Honors and Awards

  • Fellow, Medical Scientist Training Program, 1976-1982
  • Goldblatt Award (for outstanding research by a medical student) 1983
  • Fellow, Pathobiology Training Grant, 1985-86
  • National Health Research Service Fellowship, 1986-1987
  • J.P. Morgan Foundation Grant 1993
  • William D. Tigertt Endowed Chair in Pathology 2002

Professional Organization Memberships

  • American Association for Cancer Research
  • College of American Pathologists
  • American Association for the Advancement of Science
  • Society for Basic Urological Research
  • Southwest Oncology Group (SWOG)
  • Houston Society of Clinical Pathologists

Representative Publications

  • Wang, J., Cai, Y., Ren C., and Ittmann, M. 2006. Expression of variant TMPRSS2/ERG fusion mRNAs is associated with aggressive prostate cancer. Cancer Res 66:8347-8351
  • Agoulnik, I., Vaid, A., Nakka, M., Alvarado, M., Bingman W., Erdem, H., Frolov, A., Smith, C., Ayala, G., Ittmann, M., and Weigel, N. 2006. Increased Expression of the Androgen Receptor Coactivator TIF2 is Associated with Biochemical Recurrence and Androgen Independence in Prostate Cancer. Cancer Res. 66:10594-10602
  • Wang, J., Weng, J., Cai, Y., Penland, Liu, M., and Ittmann, M. 2006. The prostate specific G-protein coupled receptors PSGR and PSGR2 are prostate cancer biomarkers that are complementary to a-methylacyl-CoA racemase. Prostate 66:847-57
  • Weng, J., Wang, J., Hu, X., Cai, Y., Ittmann, M., and Liu, M. 2005. PSGR2, a novel G-protein coupled receptor, is overexpressed in prostate cancer. Int J Cancer. 118:1471-1480
  • Zhou, H., Yan, J., Luo, W., Ayala, G., Lin, S., Erdeme, H., Ittmann, M., Tsai, S., and Tsai, M. 2005. SRC-3 is an important regulator of prostate cancer cell proliferation and survival. Cancer Res. 65:7976-7983
  • Agoulnik, I., Vaid, A., Bingman, W., Erdeme, H., Frolov, A., Smith, C., Ayala, G., Ittmann, M., and Weigel, N. 2005. A role for SRC-1 in promoting prostate cancer cell growth and tumor progression. Cancer Res. 65:7959-7967
  • Ozen, M and Ittmann, M. 2005. Increased expression and activity of CDC25C phosphatase and an alternatively spliced variant in prostate cancer. Clin Cancer Res. 11:4701-4706
  • Kwabi-Addo, B., Ozen, M., and Ittmann, M. 2004. The role of fibroblast growth factors and their receptors in prostate cancer. Endocrine-related Cancer 11:709-724
  • Wang, J., Stockton, D., and Ittmann, M. 2004. The FGFR-4 Arg388 allele is associated with prostate cancer initiation and progression. Clin Cancer Res. 10: 6169-6178
  • Kwabi-Addo, B., Wang, J., Erdem, H., Vaid, A., Castro, P., Ayala, G., and Ittmann, M. 2004. Expression of Sprouty1, an inhibitor of fibroblast growth factor signal transduction, is decreased in human prostate cancer. Cancer Res. 64:4728-4735
  • Polnaszek, N., Kwabi-Addo, B., Peterson, L., Ozen, M., Greenberg, N., Ortega, S., Basilico, C., and Ittmann, M. 2003. Fibroblast growth factor 2 promotes tumor progression in an autochthonous mouse model of prostate cancer. Cancer Res. 63: 5724-5760
  • Ozen, M., Giri, D., Ropiquet, F., Mansukhani, A.,and Ittmann, M. 2001. Role of fibroblast growth factor receptor signaling in prostate cancer cell survival. J. Natl. Canc. Instit. 93:1783-1790
  • Kwabi-Addo, B., Giri, D., Schmidt, K., Podsypanina, K., Parsons, R., Greenberg, N., and Ittmann, M. 2001. Haploinsufficiency of the Pten tumor suppressor gene promotes prostate cancer progression. Proc Natl Acad Sci U S A 98:11563-11568
Michael Ittmann M.D. Ph.D.

E-mail this page to a friend